Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the vesting of awards under the 2008 GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation vesting outcomes rather than consolidated financial performance.
Material Changes and Performance Outcomes
The filing details the results of the three-year performance period (January 1, 2008, to December 31, 2010) for the 2008 Performance Share Plan:
- EPS Performance: Conditions were not met, resulting in 50% of the total award lapsing.
- TSR Performance: 35% of the portion subject to Total Shareholder Return (TSR) vested, equating to 17.5% of the full award.
- Overall Vesting: Only 17.5% of the total 2008 awards vested; the remaining 82.5% lapsed.
Management Commentary and Risks
Management commentary is limited to the mechanical explanation of the vesting formula and the specific outcome for the 2008 awards. No forward-looking guidance, strategic outlook, or discussion of general business risks is included in this specific notification.
Important Facts for Investors to Verify
- Confirm the specific EPS targets that were not met during the 2008-2010 period.
- Verify the exact TSR performance percentage achieved relative to the peer group benchmark.
- Review the total number of shares issued to other senior executives, as the filing only lists specific figures for Mrs. V A Whyte (371 vested, 689 lapsed under TSR, 1,060 lapsed under EPS).